Use of interferon gamma for the treatment of cardiac hypertrophy

摘要

The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-y). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.